Amgen Merges R&D and AI Leadership as Global Pharma Embeds Generative AI Into Research Strategy
Amgen restructured its entire R&D function by placing AI and research under a single executive, James Bradner — one of the clearest signals yet that global pharma is treating AI as core infrastructure rather than a support tool. At AACR 2026, AI-native biotechs Rakovina Therapeutics and Revolution Medicines presented preclinical data targeting oncology problems that have resisted conventional drug design for decades. The shift is structural: AI is now shaping research strategy, not just accelera
Salvado•